Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RVMD | CLUSTER | neutral | 3/10 | Two insiders at Revolution Medicines, General Counsel Jeff Cislini and Director Mark Goldsmith, sold a combined ~$22.5M | Aug 26, 2026 |
| MEDP | CLUSTER | bearish | 5/10 | A cluster of insider selling at Medpace (MEDP) over the past week saw the CEO, CFO, and two directors sell a combined $1 | Aug 26, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider sales at Twist Bioscience, totaling ~$2.50M over a week, with the CEO, CFO, COO, and other senior e | Aug 26, 2026 |
| ARDX | CLUSTER | neutral | 2/10 | Seven ARDX insiders, including the CEO and CFO, sold a total of $229K in open-market sales on August 21, 2026, all at $3 | Aug 26, 2026 |
| PGEN | CLUSTER | bearish | 4/10 | Precigen insiders show a mixed cluster: Director Nancy Agee made a small $25K open-market buy, while COO Rutul Shah sold | Aug 26, 2026 |
| REGN | COURT-RULING | bullish | 5/10 | A federal magistrate judge partially granted and partially denied motions to quash subpoenas served by Regeneron on non- | Aug 25, 2026 |
| CELU | PRESS-RELEASE | bearish | 7/10 | Celularity Inc. disclosed it received a Nasdaq delinquency notice for failing to file its Q1 and Q2 2026 quarterly repor | Aug 25, 2026 |
| MRK | COURT-RULING | bearish | 5/10 | Merck lost its constitutional challenge to the IRA's Medicare Drug Price Negotiation Program in D.C. District Court. The | Aug 25, 2026 |
| ARDX | CLUSTER | neutral | 2/10 | Six ARDX insiders, including CEO Michael Raab and the Chief Commercial Officer, collectively sold $226K in open-market s | Aug 25, 2026 |
| PGEN | CLUSTER | neutral | 2/10 | Precigen (PGEN) insiders showed mixed activity in a 7-day cluster: Director Nancy Agee made a small open-market purchase | Aug 25, 2026 |
| OMER | CLUSTER | neutral | 3/10 | Two insiders at Omeros (VP of Finance and a Director) sold a combined $466K in open-market shares over two days, followi | Aug 25, 2026 |
| ENSC | 8-K | bearish | 6/10 | Ensysce Biosciences filed an 8-K disclosing three Nasdaq compliance updates. Nasdaq confirmed the company now complies w | Aug 25, 2026 |
| MNPR | 144 | neutral | 3/10 | Director Raymond Anderson filed a Form 144 notice of intent to sell 6,284 shares of Monopar Therapeutics common stock, w | Aug 25, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $177K in open-market shares over a week, with Rothblatt also ex | Aug 25, 2026 |
| ELAN | CLUSTER | bullish | 6/10 | Elanco Animal Health insiders made $1.03M in net open-market purchases over the past week, led by Director Lawrence Kurz | Aug 25, 2026 |
| TBPH | DEFA14A | neutral | 4/10 | Theravance Biopharma filed a DEFA14A (additional definitive proxy soliciting material) on August 25, 2026, making availa | Aug 25, 2026 |
| RGNX | 8-K | neutral | 3/10 | REGENXBIO appointed Greg Ciongoli as a Class II director and accepted the resignations of Jean Bennett and Jerry Karabel | Aug 25, 2026 |
| BCAX | 8-K | neutral | 2/10 | Bicara Therapeutics entered into a sub-sublease agreement with Wayfair LLC for approximately 35,090 square feet of offic | Aug 25, 2026 |
| MRNA | ANALYST-UPGRADE | mixed | 1/10 | Wolfe Research double-upgraded MRNA from Underperform to Peer Perform on August 25, 2026, a notable shift from a bearish | Aug 25, 2026 |
| LKFT | 6-K | neutral | 4/10 | Lakefront Biotherapeutics announced two developments on August 24, 2026: the FDA granted Orphan Drug Designation to gamg | Aug 25, 2026 |
| ZYME | 8-K | bullish | 8/10 | Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii)-conta | Aug 25, 2026 |
| APLM | CLUSTER | bullish | 8/10 | Three C-suite insiders at Apollomics Inc. (APLM) collectively purchased $2.25M in open-market stock at $15.00/share over | Aug 25, 2026 |
| GRML | INSIDER-BUY | bearish | 7/10 | CFO Jeff LeBlanc purchased $136K of GRML stock at $9.72/share in an open-market transaction, representing 0.43% of the c | Aug 25, 2026 |
| MTNB | 425 | bearish | 6/10 | Matinas BioPharma filed a 425 prospectus communication containing a sponsored Wall Street Wire report promoting GH Power | Aug 25, 2026 |
| AZN | 6-K | neutral | 3/10 | AstraZeneca priced a €2.55 billion bond offering across four tranches via its subsidiary AstraZeneca Finance LLC, with p | Aug 25, 2026 |
| BTAI | 8-K | bearish | 8/10 | BioXcel Therapeutics entered into the Fourteenth Amendment to its Oaktree-led credit agreement, securing $1.25M in addit | Aug 25, 2026 |
| SEPN | 8-K | neutral | 3/10 | Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026. Dr. Patni brings over 25 year | Aug 25, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex reported a net income of $7.8M ($0.08/share) for its fiscal Q3 2026, compared to a net loss of $13.2M ($-0.16/sha | Aug 25, 2026 |
| AVXL | PRESS-RELEASE | neutral | 5/10 | Anavex Life Sciences reported a GAAP net income of $7.8M for Q3 fiscal 2026, driven by a reversal of stock-based compens | Aug 25, 2026 |
| MOLN | 6-K | neutral | 4/10 | Molecular Partners AG reported H1 2026 financial results, showing a net loss of CHF 26.7 million (improved from CHF 37.2 | Aug 25, 2026 |